XKRX
000250
Market cap4.25bUSD
Oct 08, Last price
243,500.00KRW
1D
1.04%
1Q
21.99%
Jan 2017
1,981.20%
IPO
4,844.16%
Name
Sam Chun Dang Pharm Co Ltd
Chart & performance
P/E
1,083.22
P/S
24.59
EPS
224.79
Div yield, %
0.02%
Shrs. gr., 5y
1.60%
Rev. gr., 5y
6.79%
Revenues
231.79b
+9.89%
Net income
5.26b
P
CFO
9.79b
-55.02%
Dividend
Dec 29, 202550 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and produces a wide variety of medications. Its product range features antibiotics, treatments for cardiovascular and respiratory conditions, drugs for the digestive system and ophthalmic use, as well as anti-inflammatory agents. The company was founded on December 29, 1943, and its main operations are based in Hwaseong-si, South Korea.
Key people
Vice President
Yin Seok Jeon
Chief Executive Officer, Vice President, Director · since 2022
Byeong Jip Ha
Managing Director · since 2023
Dae Wuk Kim
Managing Director · since 2009
Sang Ho Shim
Managing Director · since 2022
Oh Seok Gwon
Internal Auditor · since 2025
Yin Seok Hwang
Assistant Managing Director · since 2024
Geon Jung Hwang
Internal Auditor
Hyeong Gyun Jeon
Assistant Managing Director
Gi Beom Lee
Assistant Managing Director · since 2023
Gwang Jin Yim
Assistant Managing Director · since 2009
Yeong Gil Yoo
Assistant Managing Director · since 2022
Hyeong Jin Yoon
Assistant Managing Director · since 2022
Jeon Gyo Park
Co-Chief Executive Officer, Director · since 2012
Min Hyeong Park
Chief Financial Officer, Assistant Managing Director · since 2025
Jeong Ho Yoo
Assistant Managing Director · since 2025
Dae Yin Yoon
Chairman of the Board · since 2022
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||